Search
GlaxoSmithKline: FDA Approves Broader Use Application for Arexvy, a Respiratory Syncytial Virus Vaccine
2025-07-14 /
Read about 0 minute
Author：小编
GlaxoSmithKline (GSK) has announced that the U.S. Food and Drug Administration (FDA) has accepted its application to expand the use of Arexvy, a respiratory syncytial virus (RSV) vaccine. The approval now extends the indication for Arexvy to include high-risk adults aged 18-49. Previously, Arexvy was approved in the United States for use in individuals aged 60 and older, as well as high-risk individuals aged 50-59, to prevent lower respiratory tract diseases caused by RSV.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
